AngioDynamics Medicare coverage for NanoKnife IRE in prostate, liver cancer takes effect July 2026

AngioDynamics, Inc.

AngioDynamics, Inc.

ANGO

0.00
  • AngioDynamics’ NanoKnife IRE gained a Medicare coverage framework under Palmetto GBA’s final LCD L40205, effective July 5, 2026.
  • Coverage applies to favorable intermediate-risk prostate cancer (grade group 2) and metastatic colorectal cancer to the liver in select cases.
  • The decision supports reimbursement access in Palmetto GBA jurisdictions, a key step toward broader payer adoption.
  • Category I CPT codes for IRE in prostate and liver procedures take effect Jan. 1, 2026, enabling standardized billing with RVUs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260528366815) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.